December 17, 2015.
Reuters reports that Martin Shkreli, the controversial chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals, was arrested in New York today on securities fraud charges involving his former hedge fund, MSMB Capital Management, and a pharma company he previously headed, Retrophin Inc. A Reuters reporter witnessed Shkreli's arrest at the Murray Hill Tower Apartments in Manhattan, NY. He FBI agents escorted Shkreli, who was wearing a hoodie, into a car. FBI spokeswoman Kelly Langmesser later confirmed the arrests of both Shkreli and Evan Greebel, a former partner at law firm Katten Muchin Rosenmann, which acted as Retrophin's outside counsel. Turing and KaloBios have so far declined to comment on the news. See the Reuters report here.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.